Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: A matched analysis
| Autor: | Saab, Sammy, Jimenez, Melissa, Bau, Sherona, Goo, Tyralee, Zhao, Difan, Durazo, Francisco, Han, Steven, El Kabany, Mohammed, Kaldas, Fady, Tong, Myron J, Busuttil, Ronald W |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Liver Cirrhosis
Adult Male Matched-Pair Analysis Clinical Sciences Antiviral Agents fibrosing cholestatic hepatitis Postoperative Complications patient survival Drug Therapy Recurrence Ribavirin antiviral therapy Humans Chronic Retrospective Studies Aged Intrahepatic Cholestasis Graft Survival Middle Aged Hepatitis C Liver Transplantation liver transplant Treatment Outcome Case-Control Studies Combination Female Surgery Sofosbuvir Follow-Up Studies |
| Zdroj: | Saab, S; Jimenez, M; Bau, S; Goo, T; Zhao, D; Durazo, F; et al.(2015). Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: A matched analysis. Clinical Transplantation, 29(9), 813-819. doi: 10.1111/ctr.12584. UCLA: Retrieved from: http://www.escholarship.org/uc/item/8kz98493 Clinical transplantation, vol 29, iss 9 |
| Popis: | © 2015 John Wiley & Sons A/S. Background: Fibrosing cholestatic hepatitis (FCH) is an uncommon but potentially fatal complication of recurrent hepatitis C (HCV) in liver transplant recipients. Methods: We matched the treatment outcomes of 10 liver transplant recipients who developed FCH with those of 10 recipients with recurrent HCV without FCH treated with sofosbuvir and ribavirin. Results: Baseline mean alanine transaminase, aspartate transaminase, alkaline phosphatase, and total bilirubin were 186 U/L, 197 U/L, 243 U/L, and 6.7 mg/dL, respectively, in the FCH recipients and 82 U/L, 60 U/L, 110 U/L, and 0.99 mg/dL, respectively, in non-FCH recipients. The sustained viral response in FCH and non-FCH recipients was 40% and 80%, respectively. One-yr patient and graft survival rates were 90% and 80%, respectively, in FCH recipients, and 100% in non-FCH recipients. Seven FCH and six non-FCH recipients were treated for anemia with blood transfusion and/or erythropoietin growth factors. Conclusion: Our results suggest that the use of sofosbuvir and ribavirin is effective and tolerable in liver transplant recipients treated for recurrent FCH. There is a trend of lower sustained viral response, patient survival, and graft survival in the FCH recipients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|